Form 4: Neogenomics Executive Alicia Olivo Reports Stock Transactions
SEC Form 4 Filing
Alicia Olivo, General Counsel of Neogenomics, reports the surrender of shares to cover tax obligations and details of stock options and restricted stock units.
Summary
- Alicia Olivo, General Counsel of Neogenomics Inc., filed a Form 4 detailing changes in beneficial ownership.
- On August 1, 2024, Ms. Olivo surrendered 14 shares of common stock to cover tax obligations related to the vesting of restricted stock.
- The report also details Ms. Olivo's holdings of various stock options and restricted stock units (RSUs) with different exercise prices and expiration dates.
- Ms. Olivo also acquired 378 shares pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP).
- The filing includes information on performance stock units (PSUs) granted to Ms. Olivo, which may vest based on the achievement of certain share growth and revenue growth goals.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The continued holding of equity suggests alignment with company goals.
Positives
- The reporting person's continued holding of a significant number of stock options and restricted stock units indicates alignment with the company's long-term success.
- The acquisition of shares through the ESPP demonstrates confidence in the company's future.
Future Outlook
The vesting of performance stock units is contingent upon the achievement of certain share growth and revenue growth goals, indicating a focus on future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is specific to Neogenomics and doesn't provide direct insight into broader industry trends.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the biotechnology and diagnostics industries.
- Companies like Exact Sciences, Guardant Health, and Invitae also utilize stock-based compensation to incentivize their executives.
- The vesting schedules and performance criteria for PSUs are typical for companies seeking to align executive compensation with shareholder value creation.
Stakeholder Impact
- Shareholders are informed about the transactions of a key executive, providing transparency into insider activity.
- Employees may be impacted by the vesting of stock options and RSUs, which can affect morale and retention.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options and 19,508 performance stock units and 19,508 restricted stock units. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options and 25,330 performance stock units and 25,329 restricted stock units. |
| 08/01/2024 | Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the vesting of restricted stock. |
| 08/05/2024 | Date of the report. |
| 05/11/2026 | Performance Stock Unit vesting date. |
| 09/30/2026 | Stock options expire. |
| 05/01/2027 | Stock options expire. |
| 02/23/2027 | Performance Stock Unit vesting date. |
| 05/01/2028 | Stock options expire. |
| 08/01/2028 | Stock options expire. |
| 05/01/2029 | Stock options expire. |
| 09/01/2029 | Stock options expire. |
| 05/11/2030 | Stock options expire. |
| 02/23/2034 | Stock options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.